Zymeworks Inc. Common Stock


Prices are adjusted according to historical splits.

Zymeworks Inc. Common Stock Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$556.37 million
Book Value:
Revenue TTM:
$446.14 million
Operating Margin TTM:
Gross Profit TTM:
$203.78 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Zymeworks Inc. Common Stock had its IPO on 2017-04-28 under the ticker symbol ZYME.

The company operates in the Healthcare sector and Biotechnology industry. Zymeworks Inc. Common Stock has a staff strength of 304 employees.

Stock update

Shares of Zymeworks Inc. Common Stock opened at $8.5 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $8.38 - $8.68, and closed at $8.67.

This is a +2.12% increase from the previous day's closing price.

A total volume of 210,784 shares were traded at the close of the day’s session.

In the last one week, shares of Zymeworks Inc. Common Stock have slipped by -1.48%.

Zymeworks Inc. Common Stock's Key Ratios

Zymeworks Inc. Common Stock has a market cap of $556.37 million, indicating a price to book ratio of 1.7819 and a price to sales ratio of 13.3063.

In the last 12-months Zymeworks Inc. Common Stock’s revenue was $446.14 million with a gross profit of $203.78 million and an EBITDA of $180.72 million. The EBITDA ratio measures Zymeworks Inc. Common Stock's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Zymeworks Inc. Common Stock’s operating margin was 39.16% while its return on assets stood at 21.19% with a return of equity of 45.67%.

In Q1, Zymeworks Inc. Common Stock’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1756.9%.

Zymeworks Inc. Common Stock’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $2.88 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zymeworks Inc. Common Stock’s profitability.

Zymeworks Inc. Common Stock stock is trading at a EV to sales ratio of 5.8898 and a EV to EBITDA ratio of -0.8146. Its price to sales ratio in the trailing 12-months stood at 13.3063.

Zymeworks Inc. Common Stock stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$600.74 million
Total Liabilities
$67.32 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Zymeworks Inc. Common Stock ended 2023 with $600.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $600.74 million while shareholder equity stood at $-583116000.00.

Zymeworks Inc. Common Stock ended 2023 with $0 in deferred long-term liabilities, $67.32 million in other current liabilities, 909916000.00 in common stock, $-583116000.00 in retained earnings and $12.02 million in goodwill. Its cash balance stood at $181.58 million and cash and short-term investments were $412.38 million. The company’s total short-term debt was $3,372,000 while long-term debt stood at $0.

Zymeworks Inc. Common Stock’s total current assets stands at $426.37 million while long-term investments were $72.47 million and short-term investments were $159.21 million. Its net receivables were $66.92 million compared to accounts payable of $6.43 million and inventory worth $0.

In 2023, Zymeworks Inc. Common Stock's operating cash flow was $0 while its capital expenditure stood at $386000.

Comparatively, Zymeworks Inc. Common Stock paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Zymeworks Inc. Common Stock stock is currently trading at $8.67 per share. It touched a 52-week high of $10.8 and a 52-week low of $10.8. Analysts tracking the stock have a 12-month average target price of $14.

Its 50-day moving average was $9.08 and 200-day moving average was $7.83 The short ratio stood at 11.73 indicating a short percent outstanding of 0%.

Around 499.1% of the company’s stock are held by insiders while 10111.7% are held by institutions.

Frequently Asked Questions About Zymeworks Inc. Common Stock

The stock symbol (also called stock or share ticker) of Zymeworks Inc. Common Stock is ZYME

The IPO of Zymeworks Inc. Common Stock took place on 2017-04-28

Similar Industry Stocks (Biotechnology)

Last Price
Aditxt Inc. (ADTX)
cMoney Inc (CMEY)
Inogen Inc (INGN)

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.


114 East 4th Avenue, Vancouver, BC, Canada, V5T 1G4